BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Week in Review: Abcam plc (ABC.L) Pays $170 Million for China-Connected Epitomics


3/12/2012 11:00:43 AM

March 10, 2012 -- Abcam will pay $170 million to buy Epitomics, a US mAb pharma with a China manufacturing facility; Jiangxi Boya Bio-Pharma completed a $60 million IPO on the ChiNext exchange; 3SBio will form a $20 million JV with DaVita to set up dialysis clinics in China; EntreMed reacquired the China rights to its leading cancer drug candidate; Shanghai Duyiwei Biotech will develop mAb cancer drugs with Apexigen of California; Wuhan Kindstar Diagnostics raised $20 million in a C round from western investors; Qiagen will co-market its digene HPV Test in China with KingMed Diagnostics; Wen Jiabao, China’s Premier, announced significant increases in the PRC’s investment into basic research and technology for 2012; Roche’s China revenues jumped 35% in 2011; GlaxoSmithKline is looking at a range of strategies to build its China presence; and Aslan Pharma selected PharmaNet/i3 to conduct Phase I and II clinical trials for two cancer drug candidates. More details….

Stock Symbols: (AIM: ABC) (SHA: 300294) (NSDQ: SSRX) (NYSE: DVA) (NSDQ: ENMD) (NSDQ: QGEN) (VS: ROG) (NYSE: GSK)


Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->